~~<i id='BBE14E6D3E'><strike id='BBE14E6D3E'><tt id='BBE14E6D3E'><pre id='BBE14E6D3E'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：focus 2025-09-30 04:43:04 Page View：41916

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Humana, CVS hope to turn members into patients at clinics
Next article： Peter Hotez and the public health issue of online harassment

explore

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

8:14FormerU.S.PresidentDonaldTrumpisdisplayedonascreenduringameetingoftheSelectCommitteetoInvestigat

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

The mammogram wars are not over

AdobeNewbreastcancerscreeningguidelinesfromtheUnitedStatesPreventiveServicesTaskForcegivetheimpressi